Send us Feedback

OSI Pharmaceuticals (OSIP)
Analysis
SUMMARY
BULLS
BEARS
TOPICS
Data
DATA CENTRAL
STOCK CHART
Financials
SEC FILINGS
BALANCE
INCOME
CASH FLOW
QUOTE AND NEWS
Astellas chops OSI, Perseid ops in global R&D restructuring
FierceBiotech  May 14  Comment 
Tokyo-based Astellas Pharma is rolling out a major R&D restructuring effort, shuttering facilities at its OSI Pharmaceuticals and Perseid Therapeutics subsidiaries and cutting back its work at the Astellas Research Institute of America to focus...
Astellas mulls sale of subsidiary
FierceBiotech  Jan 10  Comment 
Astellas may offload some of the assets it acquired in its $4 billion buyout of OSI Pharmaceuticals. In a release, the company said it's mulling the strategic alternatives for subsidiary Prosidion, which it acquired in the course of its OSI deal....
Astellas to keep some OSI Long Island ops
FiercePharma  Oct 6  Comment 
Astellas has confirmed that it will keep 90 of the 240 employees at OSI Pharmaceuticals' operations in Farmingdale, NY. "By providing OSI employees with more clarity regarding the plans for the integration and organizational decisions, we hope to...
Astellas to shutter NY facilities, cut jobs
FiercePharma  Jul 30  Comment 
Astellas Pharma is the latest drugmaker to plan a shutdown of U.S. facilities. The Japanese company will shutter operations in Ardsley and Melville, NY, both of which it acquired in the $4 billion buyout of OSI Pharmaceuticals, Dow Jones...
OSI Pharma (OSIP) Updates Conversion Date on 2% Convertible Senior Notes Due 2025
StreetInsider.com  Jun 18  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/OSI+Pharma+%28OSIP%29+Updates+Conversion+Date+on+2%25+Convertible+Senior+Notes+Due+2025/5743188.html for the full story.
Business › Astellas' buyout bid for U.S. cancer drugmaker OSI succeeds
Japan Today  Jun 4  Comment 
Astellas Pharma Inc said Thursday its buyout bid for U.S. cancer drugmaker OSI Pharmaceuticals Inc has succeeded, as it has secured OSI shareholders' consent to…
Astellas Extends Tender Offer for OSI
New York Times  Jun 3  Comment 
Astellas Pharma of Japan said Thursday that it had wrapped up its initial tender offer for shares in OSI Pharmaceuticals, coming one step closer to wrapping up the $4 billion all-cash deal that will drive Astellas's growth in oncology treatments.
Astellas gets 87 pct of OSI shares in sweetened bid
Reuters  Jun 3  Comment 
S&P Announces Changes to US Indices: TSCO for OSIP in S&P MidCap 400, HITK for TSCO in SmallCap 600
StreetInsider.com  May 26  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/S%26P+Announces+Changes+to+US+Indices%3A+TSCO+for+OSIP+in+S%26P+MidCap+400%2C+HITK+for+TSCO+in+SmallCap+600/5678089.html for the full story.
Another Major Winner for those who follow me
Penny Stock DD  May 18  Comment 
I have mentioned this stock many times prior to now as one to Watch. Well here is the news and I was "dead on" . Japan's Astellas Pharma Is the Latest Company to Go Global to Dodge Patent Problems By Kerri Shannon, Associate Editor, Money...
Astellas May Stem Drug-Sales Drop With OSI Purchase (Correct)
BusinessWeek  May 18  Comment 
Astellas Pharma Inc., Japan’s second- biggest drugmaker, may stem a revenue drop caused by dwindling demand for its top-selling drugs with the planned $4 billion purchase of OSI Pharmaceuticals Inc., Nomura Holdings Inc. said.
Astellas Offer of $4 Billion Ends Pursuit of OSI (Correct)
BusinessWeek  May 18  Comment 




RELATED WIKI ARTICLES

Related Articles

more ▼WIKI ANALYSIS
 
TOP CONTRIBUTORS
Sr. Director
Grant Zeng
www.zacks.com

OSI Pharmaceuticals, Inc. (OSIP) is a biotechnology company focused on the discovery, development and commercialization of high-quality, next-generation oncology products that both extend and improve the quality of life for patients worldwide. The company's leading drug is Tarceva, which it has developed in collaboration with Genentech (DNA) and Roche Holdings. Tarceva (erlotinib HCl), a small molecule inhibitor of the epidermal growth factor receptor (EGFR), is designed to specifically block the activity of the HER1/EGFR protein, which is often over-expressed or mutated in many solid cancerous tumors. OSI Pharmaceuticals believes the drug may be useful in treating a wide range of cancer patients. During the fourth quarter of 2005, OSI Pharmaceuticals completed its planned acquisition of Eyetech Pharmaceuticals. Since that time the eye business and sales of Macugen have tanked. The acquisition of Eyetech has been a complete failure and significant shareholder value has been destroyed. Just over a year after the deal closed, OSI now records the Eyetech business as discontinued operations. Management plans to exit the eye business altogether in 2008.




References

Retrieved from "http://www.wikinvest.com/stock/OSI_Pharmaceuticals_(OSIP)"
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki